Literature DB >> 16296741

Targeted polymers for gene delivery.

Jeffery A Hughes1, Gururaj A Rao.   

Abstract

Over the past decade, significant research has been done in the area of polymer-mediated gene delivery. Synthesis of new polymers and modifications to existing polymers has resulted in polyplexes with improved in vitro and in vivo transfection efficiencies. Targeting has been an important aspect of this research, and various strategies for obtaining selective and enhanced gene delivery to the target site have been evaluated. This review covers the different aspects involved in polyplex targeting. Development of targeted polyplexes involves a careful consideration of the target site, the targeting ligand and the physicochemical properties of the polyplex itself. The need to redirect the polyplexes by using the 'shield and target' approach by reducing nonspecific interactions with negatively charged components, while conferring specificity by incorporating targeting ligands, is discussed. Basic chemistry involved in modifying polymers is covered and examples of targeting strategies used for tissue-specific gene delivery are discussed. Targeting is also discussed in the broader context of developing safe and effective polymeric vectors for in vivo gene delivery. Maximum benefit of targeting can be obtained when it is used as part of a multi-functional complex containing elements designed to improve gene delivery and reduce overall toxicity of the polyplex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16296741     DOI: 10.1517/17425247.2.1.145

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  6 in total

1.  EphA2 targeting peptide tethered bioreducible poly(cystamine bisacrylamide-diamino hexane) for the delivery of therapeutic pCMV-RAE-1γ to pancreatic islets.

Authors:  Katherine S Blevins; Ji Hoon Jeong; Mei Ou; Jonathan H Brumbach; Sung Wan Kim
Journal:  J Control Release       Date:  2011-10-28       Impact factor: 9.776

Review 2.  Personalized cancer approach: using RNA interference technology.

Authors:  John Nemunaitis; Donald D Rao; Shi-He Liu; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

3.  Localized delivery of antisense oligonucleotides by cationic hydrogel suppresses TNF-α expression and endotoxin-induced osteolysis.

Authors:  Lei Dong; Zhen Huang; Xing Cai; Jiawei Xiang; Yi-An Zhu; Rui Wang; Jiangning Chen; Junfeng Zhang
Journal:  Pharm Res       Date:  2010-12-08       Impact factor: 4.200

Review 4.  Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.

Authors:  Daniel De Paula; M Vitória L B Bentley; Ram I Mahato
Journal:  RNA       Date:  2007-02-28       Impact factor: 4.942

5.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12

6.  RNAi Therapeutics in Autoimmune Disease.

Authors:  Kaleb M Pauley; Seunghee Cha
Journal:  Pharmaceuticals (Basel)       Date:  2013-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.